InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

- Current share price for PYC : $1.555

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1,529 Notification of cessation of securities - PYC 18 Jun 2026 8:26AM $1.335 $1.555 risen by 16.48%
$1,529 Becoming a substantial holder 16 Jun 2026 4:29PM $1.270 $1.555 risen by 22.44%
$1,529 Company Secretary Appointment/Resignation 15 Jun 2026 3:01PM $1.225 $1.555 risen by 26.94%
$1,529 Notice of General Meeting/Proxy Form 12 Jun 2026 3:55PM $1.215 $1.555 risen by 27.98%
$1,529 Change to CEO remuneration 26 May 2026 7:23PM $1.380 $1.555 risen by 12.68%
$1,529 2026 Q2 Investor Webinar Presentation 22 May 2026 9:17AM $1.305 $1.555 risen by 19.16%
$1,529 Ceasing to be a substantial holder 18 May 2026 7:06PM $1.325 $1.555 risen by 17.36%
$1,529 Investor Webinar 12 May 2026 9:07AM $1.265 $1.555 risen by 22.92%
$1,529 Notification of cessation of securities - PYC 11 May 2026 6:56PM $1.265 $1.555 risen by 22.92%
$1,529 PKD - Initiation of Multiple Dose Clinical Trial 7 May 2026 9:03AM $1.165 $1.555 risen by 33.48%
$1,529 Presentation of Ophthalmology Clinical Trial Data at ARVO 4 May 2026 9:14AM $1.225 $1.555 risen by 26.94%
$1,529 Exercise of Options and Cleansing Notice 28 Apr 2026 6:44PM $1.305 $1.555 risen by 19.16%
$1,529 Application for quotation of securities - PYC 28 Apr 2026 6:34PM $1.305 $1.555 risen by 19.16%
$1,529 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:12AM $1.310 $1.555 risen by 18.70%
$1,529 Orphan Drug Designation Granted for RP11 by EMA 27 Apr 2026 9:48AM $1.295 $1.555 risen by 20.08%
$1,529 ADOA Program - SRC Approve Progression to Multi-Dose Study 15 Apr 2026 10:53AM $1.210 $1.555 risen by 28.51%
$1,529 Change in substantial holding 1 Apr 2026 8:25PM $1.165 $1.555 risen by 33.48%
$1,529 Change of Director's Interest Notice RH 27 Mar 2026 1:17PM $1.113 $1.555 risen by 39.78%
$1,529 PKD - Presentation at World Congress of Nephrology 27 Mar 2026 9:58AM $1.170 $1.555 risen by 32.91%
$1,529 ADOA Program - Presentation at NANOS 2026 24 Mar 2026 9:01AM $1.200 $1.555 risen by 29.58%
$1,529 Regulatory Alignment on Registrational Trial Requirements 16 Mar 2026 9:19AM $1.415 $1.555 risen by 9.89%
$1,529 Change of Director's Interest Notice RH IC 10 Mar 2026 6:41PM $1.470 $1.555 risen by 5.78%
$1,529 Application for quotation of securities - PYC 9 Mar 2026 7:55PM $1.480 $1.555 risen by 5.07%
$1,529 Application for quotation of securities - PYC 6 Mar 2026 9:46AM $1.485 $1.555 risen by 4.71%
$1,529 Joint Company Secretary Appointment 4 Mar 2026 7:11PM $1.470 $1.555 risen by 5.78%

1 - 25 of 921 results

Page 1 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.